Imaging software developer Median Technologies has signed a 206,000 euro contract with a biopharmaceutical company client.
The deal covers the implementation of an exploratory imaging biomarker based on tumor volume for a phase I study on adult patients with advanced malignant solid tumors.
Progression-free survival will be measured on patients enrolled in the Response Evaluation Criteria in Solid Tumors (RECIST) study. The standard criterion for response evaluation in solid tumors is based on lesion axial diameter measurements.
Imaging data will be acquired in at least four clinical sites in Europe and the U.S., accounting for a total of 50 study participants.
